Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: GlobeNewswire
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong inhibitory activity and a potential best-in-category safety profile in a Phase 1 study, supporting advancement into planned Phase 2 patient studiesOV329 Phase 1 results selected for late-breaking poster presentation at the 2025 American Epilepsy Society (AES) annual meetingOvid’s first-in-class KCC2 direct activator portfolio is progressing on-track with first-in-human data for OV350 intravenous (IV) expected in Q4 2025 and the first-ever oral KCC2 direct activator, OV4071, anticipated to enter the clinic in Q2 2026Completed private placement of up to $175 million in gross proceeds, including initial closing of approximately $81 million, expected to extend anticipated cash runway into 2H 2028 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ovid Therap
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical OfficerGlobeNewswire
- Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 11/12/25 - Miss
OVID
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 11/7/25 - Form DEF
- OVID's page on the SEC website